Effectiveness of hypertension treatment assessed by blood pressure level achieved in primary care setting in Poland

Blood Pressure

Volumn 12, Issue 4, 2003, Pages 232-238

  Grzybowski, Adam ^a   Bellwon, Jerzy ^a   Gruchała, Marcin ^a   Stolarczyk, Łukasz ^a   Popaszkiewicz, Janusz ^a   Sobiczewski, Wojciech ^a   Rynkiewicz, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Hypertension drug therapy; Primary care; Treatment effectiveness

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPED COUNTRY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GENERAL PRACTITIONER; HEALTH CARE FACILITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL ASSESSMENT; POLAND; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PULSE PRESSURE; REST; SITTING; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE; TIME; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SURVEYS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLAND; PRIMARY HEALTH CARE; QUESTIONNAIRES; SPHYGMOMANOMETERS; TREATMENT OUTCOME;

EID: 0142125689     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050310015458     Document Type: Article

References (29)

1. Burt VL, et al. Prevalence of hypertension in the US population. Results from the third national health and nutrition surveys 1988-1991. Hypertension 1995; 25: 305-13.
2. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the Health Survey for England 1994. J Hypertens 1998; 16: 747-52.
3. The Sixth Report of the Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
4. Frohlih E. State of hypertension as we enter the 21st century. Hypertension 2000; 35: 1177-8.
5. Rywik SL, et al. Poland and U.S. Collaborative study on cardiovascular epidemiology hypertension in the community: Prevalence, awareness, treatment, and control of hypertension in the Pol-MONICA project and the U.S. Atherosclerosis risk in communities study. Ann Epidemiol 1998; 8: 3-13.
6. Broda G, et al. Pol-MONIKA Warsaw Project - long term study: distribution of blood pressure in the Warsaw population and influence of selected factors on blood pressure level. Pol Arch Med Wewn 1990; 84: 253-63.
7. Szczech R, et al. Prevalence, awareness and control of hypertension - analysis of results of participants of the Polish Hypertension Survey. Arterial Hypertens (J Pol Soc Hypertens) 2000; 4: 27-37.
8. Swales JD. Hypertension in the political arena. Hypertension 2000; 35: 1179-82.
9. Veterans Administration Cooperative Study Group on Antihypertensive Agents. JAMA 1967; 202: 1028-34.
10. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised controlled trials. Prog Cardiovasc Dis 1986; 29 Suppl 1: 99-118.
11. Sever P. The heterogeneity of hypertension: Why doesn't every patient respond to every antihypertensive drug? J Cardiovasc Pharmacol 1998; 31: S1-4.
12. 1999 World Health Organization-international Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-81
13. Menard J, Chatellier G. Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 1995; 9: S19-23.
14. Freis ED. Improving treatment effectiveness in hypertension. Arch Intern Med 1999; 159: 2517-21.
15. Chockalingan A, et al. Adherence to management of high blood pressure recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Public Health 1998; 89 Suppl 1: 5-7.
16. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9: S15-18.
17. Pajak A, et al. Occurrence of adverse effects and effectiveness of primary hypertension treatment. Arterial Hypertens (J Pol Soc Hypertens) 1999; 3: 182-91.
18. Krupa-Wojciechowska B, Narkiewicz K, Rynkiewicz A. Awareness and treatment of arterial hypertension in Poland. J Hum Hypertens 1996; 10 Suppl 3: S25-7.
19. Steward IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1: 861-5.
20. Cruicshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581-4.
21. Alderman MH, Ooi WL, Madhavan S, Cohen H. Treatment-induced blood pressure reduction and the risk of myocardial infarction. JAMA 1989; 262: 920-4.
22. Hansson L, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hyper-tension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
23. Taylor Nelson Healthcare: Copyright Cardiomonitor, 1992.
24. Prisant LM, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertensive treatment. Am Heart J 1995; 130: 359-66.
25. Materson BJ, et al. Results of combination antyhipertensive therapy after failure of each of the components. J Hum Hypertens 1995; 9: 791-6.
26. Rynkiewicz A. Combination treatment - fixed combinations in effective blood pressure control. Arterial Hypertens (J Pol Soc Hypertens) 2000; 4: 39-46.
27. Dollery CT. Pharmacological basis for combination therapy of hypertension. Ann Rev Pharmacol Toxicol 1997; 17: 311-23.
28. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens 1987; 3: 278-93.
29. Lenfant C. Reflections on hypertension control rates. a message from the director of the National Heart, Lung, and Blood Institute. Arch Intern Med 2002: 162.